Table 1.
Group A | Group B | Group C | |
---|---|---|---|
Sex (M/F) | 24/16 | 24/32 | 48/44 |
Age (years) | 56.3 ± 6.1 | 56.1 ± 6.6 | 61.7 ± 7.2∗# |
BMI (Kg/m2) | 23.8 ± 2.5 | 27.0 ± 3.6* | 24.5 ± 1.7 |
CD (year) | — | 6.10 (4.54, 8.11) | 4.73 (2.77, 7.70) |
Antihypertension drug user (%) | 4 (10%) | 31 (55.4%)** | 55 (59.8%)** |
SBP (mmHg) | 114 ± 13 | 124 ± 9 | 136 ± 18∗∗# |
DBP (mmHg) | 70 (65–75) | 72 (66–79) | 80 (80-81)∗# |
HbA1c (%) | 5.3 ± 0.3 | 6.6 ± 1.2** | 7.5 ± 1.4∗∗# |
HDL-c (mmol/L) | 0.88 (0.83–0.92) | 0.96 (0.92–1.27)* | 0.91 (0.85–1.13) |
LDL-c (mmol/L) | 2.16 (2.05–2.20) | 2.51 (1.78–2.92) | 2.17 (2.07–3.23) |
TG (mmol/L) | 1.63 (1.58–1.66) | 2.12 (1.21–4.11) | 1.70 (1.42–2.23) |
TC (mmol/L) | 4.14 (3.93–4.25) | 4.74 (4.05–4.79) | 4.11 (3.57–4.46) |
GSH (mmol/L) | 4.23 ± 0.64 | 3.18 ± 0.86 | 2.24 ± 0.73 |
MBG (mmol/L) | 6.1 ± 0.6 | 8.1 ± 2.1* | 8.0 ± 1.4** |
MAGE (mmol/L) | 2.2 (1.8, 2.8) | 2.6 (1.9, 3.5)** | 4.0 (3.3, 4.8)∗∗## |
NEGE (times) | 6.8 (6.0, 7.7) | 4.1 (3.5, 4.7)** | 4.0 (3.4, 4.8)** |
SDBG (mmol/L) | 0.8 ± 0.3 | 1.5 ± 0.4** | 2.0 ± 0.8∗∗# |
LAGE (mmol/L) | 2.9 (2.6–4.5) | 6.6 (5.8–12.4)** | 7.8 (6.1–9.9)** |
PPGE1 (mmol/L) | 2.7 (1.6–4.3) | 3.2 (1.7–9.8) | 4.6 (3.2–8.1)** |
PPGE2 (mmol/L) | 2.3 (1.7–3.5) | 2.4 (2.2–8.6) | 3.3 (2.6–5.4)* |
PPGE3 (mmol/L) | 2.2 ± 0.4 | 2.7 ± 1.1 | 4.7 ± 2.5∗∗## |
IMT (mm) | 0.6 ± 0.1 | 0.9 ± 0.3* | 1.1 ± 0.3∗∗# |
CRP (mg/L) | 1.0 (0.9–1.1) | 1.1 (1.0–2.8)* | 3.8 (2.8–5.4)∗∗## |
HOMA-IR | 1.58 (1.52–1.69) | 2.3 (1.9–9.1)** | 4.3 (3.0–4.9)** |
HBCI | 87 (82–103) | 45 (28–67)** | 80 (48–139)## |
SYNTAX score | — | 0 | 23.5 ± 5.9 |
CD: course of disease. Compared with group A, *P < 0.05, **P < 0.01; compared with group B, # P < 0.05, ## P < 0.01.